SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Read More
Tag: tisagenlecleucel
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
Read More
First children set to receive Novartis’ Kymriah
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer – will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Read More
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read More
NHS England strikes deal with Novartis on Kymriah
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
Read More
NICE says ‘no’ to Gilead’s Yescarta in draft guidelines
NHS funding for Gilead’s freshly approved CAR-T therapy Yescarta has been turned down in draft guidelines by the National Institute for Health and Care Excellence.
Read More
EU approves first CAR-T therapies
European regulators have approved Novartis’ Kymriah and Gilead’s Yescarta, enabling patients to access CAR-T therapies across the region for the first time.
Read More
CAR-T therapy could be available to NHS patients this year
NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Read More
Novartis’ Kymriah shows durable response in blood cancer
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
Read More
Novartis files CAR-T therapy in Europe
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Read More
Novartis’ Kymriah first cell therapy to win US green light
Novartis’ Kymriah has become the first ever CAR-T cell therapy to win approval in the US, bringing paediatric and young adult patients with B-cell acute lymphoblastic leukaemia a novel treatment approach.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
